Introduction: Early detection of cancers through the analysis of ctDNA could have a
significant impact on morbidity and mortality of cancer patients. However, using ctDNA for …

Assessment of cell free DNA (cfDNA) and RNA (cfRNA), circulating tumor cells (CTC) and
extracellular vesicles (EV) in blood or other bodily fluids can enable early cancer detection …

Purpose: Despite recent therapeutic advances, prognosis of patients with pancreatic
adenocarcinoma remains poor. Analyses from tumor tissues present limitations; …

Background RAS mutations are currently sought for in tumor samples, which takes a median
of almost 3 weeks in western European countries. This creates problems in clinical …

Abstract Purpose: Circulating tumor DNA (ctDNA) has been suggested as a major
prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients …

The innovation of liquid biopsy holds great potential to revolutionise cancer management
through early diagnosis and timely treatment of cancer. Integrative analysis of different …

Pancreatic cancer is currently the most lethal tumor entity and case numbers are rising. It will
soon be the second most frequent cause of cancer-related death in the Western world …

The field of cancer diagnostics has recently been impacted by new and exciting
developments in the area of liquid biopsy. A liquid biopsy is a minimally invasive alternative …

Pancreatic cancer is a highly aggressive malignancy with a climbing incidence. The majority
of cases are detected late, with incurable locally advanced or metastatic disease. Even in …

Circulating cell-free tumor DNA (ctDNA) is a promising biomarker in cancer. Ultrasensitive
technologies enable detection of low (< 0.1%) mutant allele frequencies, a pre-requisite to …